Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Mato

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGraeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C Byrd, Peter Hillmen, Paolo Ghia, et al.
The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.
The Journal of Molecular Diagnostics : JMD|March 24, 2023
Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Detailed Description of the Technical Performance, Clinical Utility, and Platform ComparisonKseniya Petrova-Drus, Mustafa Syed, Wayne Yu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 6, 2020
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, John C Byrd, Jeremy S Abramson, et al.
Blood Advances|February 5, 2024
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective studyLaura Samples, Jenna Voutsinas, Bita Fakhri, et al.
American Journal of Hematology|June 6, 2015
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohortAndrew M Evens, Jennifer A Kanakry, Laurie H Sehn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 20, 2019
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019William G Wierda, John C Byrd, Jeremy S Abramson, et al.
The New England Journal of Medicine|February 23, 2022
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase InhibitorsEric Wang, Xiaoli Mi, Meghan C Thompson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 17, 2022
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|August 9, 2020
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaGraeme A M Fraser, Asher Chanan-Khan, Fatih Demirkan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C Byrd, Peter Hillmen, Paolo Ghia, et al.
The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.
The Journal of Molecular Diagnostics : JMD|March 24, 2023
Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Detailed Description of the Technical Performance, Clinical Utility, and Platform ComparisonKseniya Petrova-Drus, Mustafa Syed, Wayne Yu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 6, 2020
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in OncologyWilliam G Wierda, John C Byrd, Jeremy S Abramson, et al.
Blood Advances|February 5, 2024
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective studyLaura Samples, Jenna Voutsinas, Bita Fakhri, et al.
American Journal of Hematology|June 6, 2015
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohortAndrew M Evens, Jennifer A Kanakry, Laurie H Sehn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 20, 2019
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019William G Wierda, John C Byrd, Jeremy S Abramson, et al.
The New England Journal of Medicine|February 23, 2022
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase InhibitorsEric Wang, Xiaoli Mi, Meghan C Thompson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 17, 2022
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022William G Wierda, Jennifer Brown, Jeremy S Abramson, et al.
Pageof 7